Harrow, Inc. (HROW) Gross Margin
- Gross margin · 12 months: Value 73.28%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 73.28% | Gross profit / revenue. Period ending 2026-06-30. $201.96M ÷ $275.59M × 100 ≈ 73.28% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 201.96M USD | Gross Profit |
| Revenue | 275.59M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 73.64M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $201.96M | $275.59M | $73.64M | 73.28% |
| 2026-03-31 | $199.11M | $268.68M | $69.57M | 74.11% |
| 2025-12-31 | $204.37M | $272.30M | $67.93M | 75.05% |
| 2025-09-30 | $186.44M | $250.04M | $63.60M | 74.56% |
| 2025-06-30 | $169.75M | $227.66M | $57.91M | 74.56% |
| 2025-03-31 | $158.64M | $212.86M | $54.22M | 74.53% |
| 2024-12-31 | $150.37M | $199.61M | $49.24M | 75.33% |
| 2024-09-30 | $122.73M | $169.14M | $46.41M | 72.56% |
| 2024-06-30 | $109.69M | $154.15M | $44.46M | 71.16% |
| 2024-03-31 | $96.75M | $138.68M | $41.92M | 69.77% |
| 2023-12-31 | $90.55M | $130.19M | $39.64M | 69.55% |
| 2023-09-30 | $79.66M | $114.17M | $34.50M | 69.78% |
| 2023-06-30 | $71.57M | $102.72M | $31.16M | 69.67% |
| 2023-03-31 | $64.89M | $92.58M | $27.69M | 70.09% |
| 2022-12-31 | $63.21M | $88.59M | $25.38M | 71.35% |
| 2022-09-30 | $64.16M | $88.45M | $24.30M | 72.53% |
| 2022-06-30 | $61.82M | $84.34M | $22.52M | 73.29% |
| 2022-03-31 | $58.75M | $79.15M | $20.41M | 74.22% |
| 2021-12-31 | $54.26M | $72.48M | $18.21M | 74.87% |
| 2021-09-30 | $49.81M | $66.88M | $17.07M | 74.48% |
| 2021-06-30 | $46.75M | $62.57M | $15.82M | 74.72% |
| 2021-03-31 | $37.89M | $52.50M | $14.61M | 72.18% |
| 2020-12-31 | $34.41M | $48.87M | $14.46M | 70.41% |
| 2020-09-30 | $32.79M | $46.88M | $14.09M | 69.94% |
| 2020-06-30 | $30.78M | $45.24M | $14.46M | 68.04% |
| 2020-03-31 | $34.22M | $50.69M | $16.48M | 67.50% |
| 2019-12-31 | $34.42M | $51.16M | $16.75M | 67.26% |
| 2019-09-30 | $32.66M | $49.95M | $17.29M | 65.39% |
| 2019-06-30 | $30.51M | $47.93M | $17.42M | 63.66% |
| 2019-03-31 | $28.45M | $44.80M | $16.35M | 63.51% |
| 2018-12-31 | $24.85M | $41.37M | $16.52M | 60.07% |
| 2018-09-30 | $21.45M | $37.33M | (m) | 57.47% |
| 2018-06-30 | $17.98M | $33.07M | (m) | 54.37% |
| 2018-03-31 | $15.32M | $29.54M | (m) | 51.87% |
| 2017-12-31 | $13.27M | $26.77M | (m) | 49.56% |
| 2017-09-30 | $12.11M | $25.23M | (m) | 48.00% |
| 2017-06-30 | $11.55M | $23.61M | (m) | 48.94% |
| 2017-03-31 | $10.72M | $21.66M | (m) | 49.49% |
| 2016-12-31 | $10.11M | $19.94M | (m) | 50.70% |
| 2016-09-30 | $8.95M | $17.65M | (m) | 50.67% |
| 2016-06-30 | $7.90M | $15.47M | (m) | 51.08% |
| 2016-03-31 | $6.09M | $12.53M | (m) | 48.56% |
| 2015-12-31 | $4.51M | $9.72M | (m) | 46.42% |
| 2015-09-30 | $3.13M | $6.76M | (m) | 46.23% |
| 2015-06-30 | $1.85M | $4.52M | (m) | 40.86% |
| 2015-03-31 | $1.12M | $3.22M | (m) | 34.81% |
| 2014-12-31 | $567.41K | $1.66M | (m) | 34.18% |
| 2014-09-30 | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) |
| 2013-12-31 | $10.00K | $10.00K | (m) | 100.00% |
| 2013-09-30 | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |